Insider Selling: Werewolf Therapeutics (NASDAQ:HOWL) Director Sells 53,416 Shares of Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 53,416 shares of the stock in a transaction on Thursday, December 4th. The stock was sold at an average price of $0.97, for a total value of $51,813.52. Following the completion of the sale, the director owned 3,068,278 shares in the company, valued at approximately $2,976,229.66. The trade was a 1.71% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Luke Evnin also recently made the following trade(s):

• On Wednesday, December 3rd, Luke Evnin sold 36,726 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.87, for a total transaction of $31,951.62.
• On Tuesday, December 2nd, Luke Evnin sold 38,043 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.89, for a total value of $33,858.27.
• On Monday, December 1st, Luke Evnin sold 39,096 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.94, for a total value of $36,750.24.
• On Friday, November 28th, Luke Evnin sold 13,014 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.99, for a total transaction of $12,883.86.
• On Wednesday, November 26th, Luke Evnin sold 38,978 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.98, for a total transaction of $38,198.44.
• On Tuesday, November 25th, Luke Evnin sold 27,297 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.92, for a total transaction of $25,113.24.
• On Monday, November 24th, Luke Evnin sold 56,992 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.98, for a total value of $55,852.16.
• On Friday, November 21st, Luke Evnin sold 41,287 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.83, for a total value of $34,268.21.
• On Thursday, November 20th, Luke Evnin sold 26,411 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.89, for a total value of $23,505.79.
• On Wednesday, November 19th, Luke Evnin sold 42,566 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.94, for a total value of $40,012.04.

Werewolf Therapeutics Stock Up 8.5%

Shares of Werewolf Therapeutics stock traded up $0.08 during trading hours on Thursday, reaching $1.00. 587,802 shares of the company were exchanged, compared to its average volume of 504,491. The firm has a market cap of $48.36 million, a PE ratio of -0.61 and a beta of 0.74. The stock’s fifty day moving average is $1.42 and its 200 day moving average is $1.33. The company has a debt-to-equity ratio of 0.73, a quick ratio of 3.87 and a current ratio of 3.87. Werewolf Therapeutics, Inc. has a 1 year low of $0.60 and a 1 year high of $2.38.

Werewolf Therapeutics (NASDAQ:HOWL) last announced its quarterly earnings results on Tuesday, November 4th. The company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.03. As a group, equities research analysts forecast that Werewolf Therapeutics, Inc. will post -1.56 earnings per share for the current year.

Hedge Funds Weigh In On Werewolf Therapeutics

Several hedge funds have recently made changes to their positions in the business. Charles Schwab Investment Management Inc. boosted its position in shares of Werewolf Therapeutics by 33.2% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 95,712 shares of the company’s stock valued at $93,000 after purchasing an additional 23,852 shares during the period. Nuveen LLC bought a new position in Werewolf Therapeutics during the first quarter valued at approximately $71,000. MPM Asset Management LLC increased its position in Werewolf Therapeutics by 0.6% during the first quarter. MPM Asset Management LLC now owns 4,309,860 shares of the company’s stock worth $4,189,000 after buying an additional 25,688 shares during the last quarter. MPM Bioimpact LLC lifted its holdings in Werewolf Therapeutics by 0.9% in the 1st quarter. MPM Bioimpact LLC now owns 2,408,810 shares of the company’s stock worth $2,341,000 after purchasing an additional 20,799 shares during the last quarter. Finally, AQR Capital Management LLC bought a new stake in Werewolf Therapeutics during the first quarter worth approximately $79,000. Institutional investors and hedge funds own 64.84% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently commented on HOWL. Weiss Ratings reissued a “sell (d-)” rating on shares of Werewolf Therapeutics in a research note on Wednesday, October 8th. Citigroup reiterated a “market outperform” rating on shares of Werewolf Therapeutics in a report on Wednesday, November 12th. JMP Securities dropped their price objective on Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating for the company in a report on Thursday, August 21st. Zacks Research downgraded Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 21st. Finally, Bank of America cut their price objective on Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a report on Tuesday, November 18th. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Werewolf Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $7.75.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.